ES2355853T3 - Solución que comprende n-acetilcisteína y ácido glucónico y métodos para reducir, tratar y/o prevenir el estrés oxidativo y la activación celular. - Google Patents
Solución que comprende n-acetilcisteína y ácido glucónico y métodos para reducir, tratar y/o prevenir el estrés oxidativo y la activación celular. Download PDFInfo
- Publication number
- ES2355853T3 ES2355853T3 ES07764759T ES07764759T ES2355853T3 ES 2355853 T3 ES2355853 T3 ES 2355853T3 ES 07764759 T ES07764759 T ES 07764759T ES 07764759 T ES07764759 T ES 07764759T ES 2355853 T3 ES2355853 T3 ES 2355853T3
- Authority
- ES
- Spain
- Prior art keywords
- solution
- concentration
- results
- oxidative stress
- acetylcysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000036542 oxidative stress Effects 0.000 title claims abstract description 27
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 title claims abstract description 24
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 235000012208 gluconic acid Nutrition 0.000 title claims abstract description 20
- 239000000174 gluconic acid Substances 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title abstract description 15
- 230000004913 activation Effects 0.000 title description 21
- 230000001413 cellular effect Effects 0.000 title description 13
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 49
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 49
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 34
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 34
- 230000020411 cell activation Effects 0.000 claims abstract description 24
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 17
- 230000017531 blood circulation Effects 0.000 claims abstract description 17
- 229960003180 glutathione Drugs 0.000 claims abstract description 17
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 17
- 239000011718 vitamin C Substances 0.000 claims abstract description 17
- 108010024636 Glutathione Proteins 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 14
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000000243 solution Substances 0.000 abstract description 34
- 239000012528 membrane Substances 0.000 abstract description 15
- 238000001802 infusion Methods 0.000 abstract description 13
- 239000000385 dialysis solution Substances 0.000 abstract description 12
- 238000002347 injection Methods 0.000 abstract description 10
- 239000007924 injection Substances 0.000 abstract description 10
- 239000000470 constituent Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 25
- 150000003254 radicals Chemical class 0.000 description 20
- 239000003642 reactive oxygen metabolite Substances 0.000 description 20
- 239000003963 antioxidant agent Substances 0.000 description 16
- 235000006708 antioxidants Nutrition 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000036470 plasma concentration Effects 0.000 description 11
- 230000008030 elimination Effects 0.000 description 10
- 238000003379 elimination reaction Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 235000003969 glutathione Nutrition 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 239000007850 fluorescent dye Substances 0.000 description 8
- 238000001631 haemodialysis Methods 0.000 description 8
- 230000000322 hemodialysis Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 229940117360 ethyl pyruvate Drugs 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000002516 radical scavenger Substances 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 5
- 102100022338 Integrin alpha-M Human genes 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 229940050410 gluconate Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000006950 reactive oxygen species formation Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 108010051842 Advanced Oxidation Protein Products Proteins 0.000 description 3
- 229940123457 Free radical scavenger Drugs 0.000 description 3
- NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 3
- 230000003305 autocrine Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000003076 paracrine Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 2
- CGVPQHIRIGIDLE-UHFFFAOYSA-N 3-(2-aminooxyphenyl)propanoic acid Chemical compound NOC1=CC=CC=C1CCC(O)=O CGVPQHIRIGIDLE-UHFFFAOYSA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000009215 host defense mechanism Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 238000013178 mathematical model Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000019499 negative regulation of cell activation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- -1 oxygen radical Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- BMLMGCPTLHPWPY-REOHCLBHSA-N (4R)-2-oxo-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSC(=O)N1 BMLMGCPTLHPWPY-REOHCLBHSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003454 advanced oxidation protein product Substances 0.000 description 1
- 229940008201 allegra Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000013931 endocrine signaling Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000002248 lipoperoxidative effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80548906P | 2006-06-22 | 2006-06-22 | |
| US805489P | 2006-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2355853T3 true ES2355853T3 (es) | 2011-03-31 |
Family
ID=38614318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07764759T Active ES2355853T3 (es) | 2006-06-22 | 2007-06-21 | Solución que comprende n-acetilcisteína y ácido glucónico y métodos para reducir, tratar y/o prevenir el estrés oxidativo y la activación celular. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100204328A1 (pl) |
| EP (1) | EP2040689B1 (pl) |
| AT (1) | ATE489950T1 (pl) |
| CA (1) | CA2655644C (pl) |
| DE (1) | DE602007010938D1 (pl) |
| ES (1) | ES2355853T3 (pl) |
| PL (1) | PL2040689T3 (pl) |
| WO (1) | WO2007147590A2 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010112547A1 (en) * | 2009-03-31 | 2010-10-07 | Gambro Lundia Ab | Dialysis precursor composition |
| CN107922922A (zh) | 2015-08-24 | 2018-04-17 | 维特罗利夫瑞典股份公司 | 培养基 |
| RU2709501C1 (ru) * | 2019-10-15 | 2019-12-18 | Виктор Александрович Сисев | Фармацевтическая композиция для парентерального капельного введения |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3583880D1 (de) * | 1984-04-09 | 1991-10-02 | Takeda Chemical Industries Ltd | Stabile interleukin-2-zusammensetzung. |
| JP3714689B2 (ja) * | 1994-10-27 | 2005-11-09 | ユニチカ株式会社 | ビリルビン測定用試薬 |
| US5871769A (en) * | 1996-01-18 | 1999-02-16 | Fleming & Company, Pharmaceuticals | Methods and compositions for the prevention and treatment of diabetes mellitus |
| IT1312086B1 (it) * | 1999-04-21 | 2002-04-04 | Zambon Spa | Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress |
| EP1062879B1 (en) * | 1999-06-26 | 2003-08-27 | B. Braun Melsungen Ag | Aqueous solution for the parenteral nutrition |
| KR100390630B1 (ko) * | 1999-07-02 | 2003-07-07 | 이희발 | 항 산화제를 함유한 복막투석액 |
| ATE311203T1 (de) * | 1999-10-15 | 2005-12-15 | Dow Global Technologies Inc | Dialyselösung die polyglycol als osmotischen mittels enthält |
| US7014990B2 (en) * | 2000-10-13 | 2006-03-21 | Ben O'Mar Arrington | Machine perfusion solution for organ and biological tissue preservation |
| US6955816B2 (en) * | 2001-11-16 | 2005-10-18 | Klysz Beatrice M | Anti-aging skin care composition and uses thereof |
| JP4894219B2 (ja) * | 2004-10-15 | 2012-03-14 | ニプロ株式会社 | ビタミンｂ群配合末梢静脈栄養輸液 |
| WO2007046757A1 (en) * | 2005-10-17 | 2007-04-26 | Gambro Lundia Ab | Extracorporeal blood cleaning |
-
2007
- 2007-06-21 ES ES07764759T patent/ES2355853T3/es active Active
- 2007-06-21 EP EP07764759A patent/EP2040689B1/en active Active
- 2007-06-21 DE DE602007010938T patent/DE602007010938D1/de active Active
- 2007-06-21 CA CA2655644A patent/CA2655644C/en not_active Expired - Fee Related
- 2007-06-21 US US12/305,481 patent/US20100204328A1/en not_active Abandoned
- 2007-06-21 PL PL07764759T patent/PL2040689T3/pl unknown
- 2007-06-21 AT AT07764759T patent/ATE489950T1/de not_active IP Right Cessation
- 2007-06-21 WO PCT/EP2007/005466 patent/WO2007147590A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE602007010938D1 (de) | 2011-01-13 |
| CA2655644C (en) | 2013-01-08 |
| EP2040689B1 (en) | 2010-12-01 |
| CA2655644A1 (en) | 2007-12-27 |
| EP2040689A2 (en) | 2009-04-01 |
| US20100204328A1 (en) | 2010-08-12 |
| PL2040689T3 (pl) | 2011-04-29 |
| WO2007147590A3 (en) | 2008-03-13 |
| WO2007147590A2 (en) | 2007-12-27 |
| ATE489950T1 (de) | 2010-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xue et al. | Glutamine therapy improves outcome of in vitro and in vivo experimental colitis models | |
| Laloux et al. | Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease? | |
| Kobylinska et al. | Biochemical indicators of hepatotoxicity in blood serum of rats under the effect of novel 4-thiazolidinone derivatives and doxorubicin and their complexes with polyethyleneglycol-containing nanoscale polymeric carrier | |
| ES2355853T3 (es) | Solución que comprende n-acetilcisteína y ácido glucónico y métodos para reducir, tratar y/o prevenir el estrés oxidativo y la activación celular. | |
| Zhang et al. | Atorvastatin combined with imipenem alleviates lung injury in sepsis by inhibiting neutrophil extracellular trap formation via the ERK/NOX2 signaling pathway | |
| Hu et al. | Postconditioning with sevoflurane ameliorates spatial learning and memory deficit via attenuating endoplasmic reticulum stress induced neuron apoptosis in a rat model of hemorrhage shock and resuscitation | |
| Huang et al. | Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs | |
| Dong et al. | A biomimetic nanomedicine alleviates liver transplant-related biliary injury by sequentially inhibiting oxidative stress and regulating macrophage polarization via Nrf-2/HO-1 and JNK pathways | |
| Yatsunami et al. | Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells | |
| ES2314056T3 (es) | Activadores de la anhidrasa carbonica para mejorar el aprendizaje y la memoria. | |
| AU2020203126B2 (en) | Pharmaceutical solution comprising dopamine for use in treating Parkinson's disease | |
| Pardo et al. | Use of charcoal hemoperfusion and hemodialysis in the treatment of methotrexate toxicosis in a dog | |
| CN103417554B (zh) | 一种抗肿瘤的药物组合物及其应用 | |
| Ott et al. | The effect of high-dose selenium on mortality and postoperative organ dysfunction in post-cardiotomy cardiogenic shock patients supported with mechanical circulatory support–A post-hoc analysis of the SUSTAIN CSX trial | |
| EP2902032A1 (en) | Liquid medicine having carbon dioxide dissolved therein, and therapeutic method using same | |
| RU2356589C1 (ru) | Способ лечения рака пищевода | |
| Yeh et al. | Alirocumab therapy effectively suppresses colorectal cancer cell Growth and invasion in nude mouse liver-PCSK9 is a key driver of PI3K/Akt/p-Bad-mediated cell proliferation and antiapoptotic signaling | |
| ES2354798T3 (es) | Preparación de combinación para el tratamiento de la septicemia. | |
| Bari | Reduction of perioperative inflammatory reaction with exogenous methane | |
| JP2024171916A (ja) | 非アルコール性脂肪性肝疾患治療薬 | |
| Alemanno | Cerebral Oedema | |
| Minko | 15 Mechanisms of Cellular Drug Resistance and Strategies to Overcome it | |
| NZ725828B2 (en) | Pharmaceutical solution comprising dopamine for use in treating parkinson's disease | |
| Bark | Aspects of sepsis/SIRS-An experimental study on fluid therapy, vitamin C and plasma volume in increased permeability | |
| Mihelsons et al. | Stress Response to Surgery and Possible Ways of Its Correction/Pacienta organisma atbilde uz kirurgisko stresu un iespejamie tas korekcijas veidi |